Boehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover ...

Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off ...

Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.

Telix paid $165 billion upfront primarily to secure ITM’s lead radioligand candidate ITM-11, which was recently rejected by ...

Roche has reported a phase 3 win for sefaxersen in kidney disease, teeing up talks with regulators about the path to approval for the Ionis Pharmaceuticals-partnered, would-be blockbuster drug ...

GSK has been operating a strategy of “balancing the West and the East” since the British pharma’s eyes were opened to the potential of licensing drugs from China a few years ago, according to an ...

Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up ...

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited ...

Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich’s ataxia (FA) portfolio while locking in three strategic ...

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive ...

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.  | Boehringer ...

Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial. The phase 2 ...